Last reviewed · How we verify
Sabin-IPV and DTaP
At a glance
| Generic name | Sabin-IPV and DTaP |
|---|---|
| Sponsor | China National Biotec Group Company Limited |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations (PHASE4)
- Study of Concomitant Administration of the sIPV and DTaP or MMR (PHASE4)
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028) (PHASE1)
- Immunogenicity of After Primary Immunization and Booster Immunization of sIPV
- A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults (PHASE1)
- A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants (PHASE4)
- Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP (PHASE4)
- Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sabin-IPV and DTaP CI brief — competitive landscape report
- Sabin-IPV and DTaP updates RSS · CI watch RSS
- China National Biotec Group Company Limited portfolio CI